•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Kodiak Sciences Inc. (KOD) Presents at UBS Global Biopharma Conference 2026 Transcript
Kodiak Sciences: Sticking With Hold As Optimistic Assumptions Are Already Priced In
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
Kodiak Sciences to Present at Three Upcoming Investor Conferences
Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review
Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?
Kodiak Sciences Inc. (NASDAQ:KOD) Stock Has Average Target Price of $104.71
11 Stocks Most Likely to See a Short Squeeze Rally
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study
Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Acquires 33,726 Shares of Company Stock
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Kodiak Sciences Inc. (NASDAQ: KOD) Advances Zenkuda Toward Filing
Why Kodiak Sciences Skyrocketed Today
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Kodiak Sciences (KOD) Soars on Positive Phase 3 DAYBREAK Study Results
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine